Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) - Pipeline Review, H1 2016

  • ID: 3753870
  • Report
  • 59 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Advinus Therapeutics Ltd.
  • Johnson & Johnson
  • MAKScientific, LLC
  • Midatech Pharma US Inc.
  • Sigma-Tau S.p.A.
  • MORE
Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) - Pipeline Review, H1 2016

Summary

‘Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) - Pipeline Review, H1 2016’, provides in depth analysis on Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) targeted pipeline therapeutics.

The report provides comprehensive information on the Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99)
- The report reviews Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) targeted therapeutics and enlists all their major and minor projects
- The report assesses Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Advinus Therapeutics Ltd.
  • Johnson & Johnson
  • MAKScientific, LLC
  • Midatech Pharma US Inc.
  • Sigma-Tau S.p.A.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) Overview

Therapeutics Development

Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) - Products under Development by Stage of Development

Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) - Products under Development by Therapy Area

Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) - Products under Development by Indication

Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) - Products under Development by Companies

Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) - Products under Development by Universities/Institutes

Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) - Companies Involved in Therapeutics Development

Advinus Therapeutics Ltd.

Johnson & Johnson

MAKScientific, LLC

Midatech Pharma US Inc.

Sigma-Tau S.p.A.

Takeda Pharmaceutical Company Limited

Zynerba Pharmaceuticals, Inc.

Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) - Drug Profiles

AM-3506 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AM-5206 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IPI-940 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-40413269 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KRN-5500 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit FAAH for Chemotherapy Induced Neuropathic Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit FAAH for Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit COX and FAAH for Oncology, Immunology and CNS Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ST-4070 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

URB-694 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

URB-937 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZYN-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) - Dormant Projects

Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) - Discontinued Products

Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) - Featured News & Press Releases

Apr 12, 2016: Cannabis and Cannabinoid Research Publishes Data Demonstrating the Degradation of Cannabidiol to Psychoactive Cannabinoids when Exposed to Simulated Gastric Fluid

Feb 25, 2016: Zynerba Pharmaceuticals Announces ZYN002 Granted Orphan Drug Designation for Fragile X Syndrome

Jan 06, 2016: Zynerba Pharmaceuticals Announces Positive Initial Results From ZYN002 CBD Gel Phase 1 Single Rising Dose Trial and Initiation of Phase 1 Multiple Rising Dose Trial

Oct 20, 2015: Zynerba Pharmaceuticals Initiates Phase 1 Clinical Trial for ZYN002 CBD Gel

Jun 16, 2014: DARA BioSciences' KRN5500 Granted Orphan Drug Designation by FDA for Treatment of Multiple Myeloma

Feb 25, 2014: DARA BioSciences' KRN5500 Receives Orphan Drug Designation From FDA

Nov 29, 2012: Dara BioSciences Submits Orphan Drug Application For KRN5500 To FDA

May 09, 2012: Dara To Advance Development Of KRN5500 For Treatment Of Cancer And Neuropathic Pain

Oct 10, 2011: DARA BioSciences Announces KRN5500 Demonstrated Significant Decrease In Intensity Of Neuropathic Pain In Patients With Cancer

Sep 15, 2011: DARA BioSciences To Present Positive Results Of KRN5500 Phase II Study At 5th Annual Therapeutics Summit

Aug 18, 2011: DARA BioSciences Receives Fast Track Designation From FDA For KRN5500 For Treatment Of Chemotherapy-Induced Neuropathic Pain In Patients With Cancer

Jun 01, 2011: Infinity To Provide Update On IPI-940

Mar 29, 2011: DARA Reports Promising Findings From Phase II Study Of KRN5500 at ADEPT

Feb 01, 2011: DARA's KRN5500 Study Results Selected For Presentation By International Conference On Accelerating Development Of Enhanced Pain Treatments

Dec 14, 2010: DARA BioSciences Reports Positive Phase II Data Of KRN5500 In Neuropathic Pain

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Advinus Therapeutics Ltd., H1 2016

Pipeline by Johnson & Johnson, H1 2016

Pipeline by MAKScientific, LLC, H1 2016

Pipeline by Midatech Pharma US Inc., H1 2016

Pipeline by Sigma-Tau S.p.A., H1 2016

Pipeline by Takeda Pharmaceutical Company Limited, H1 2016

Pipeline by Zynerba Pharmaceuticals, Inc., H1 2016

Dormant Projects, H1 2016

Dormant Projects (Contd..1), H1 2016

Discontinued Products, H1 2016

List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Advinus Therapeutics Ltd.
Johnson & Johnson
MAKScientific, LLC
Midatech Pharma US Inc.
Sigma-Tau S.p.A.
Takeda Pharmaceutical Company Limited
Zynerba Pharmaceuticals, Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll